|
**Overview**: Insulin Fasting Postprandial Panel**Introduction**: The Insulin Fasting Postprandial Panel is a diagnostic tool designed to assess insulin response using serum samples. In India, insulin resistance and hyperinsulinemia are central to type 2 diabetes (~77 million cases) and PCOS, with fasting/postprandial insulin levels helping evaluate beta-cell function and glucose disposal. High morbidity from under-testing in rural/low-SES patients with metabolic risk, limited labs, delayed lifestyle intervention leading to diabetes progression or CVD. Per endocrinology practices aligned with ICMR and RSSDI guidelines, the test employs immunoassay for fasting and postprandial insulin over 1-2 days with high accuracy, valuable for detecting early insulin dysregulation. This diagnostic falls under metabolic screening and targets patients with prediabetes, PCOS, or family diabetes, addressing accurate detection to guide diet/exercise or metformin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise insulin profiling and reducing metabolic complications. Its serum-based approach ensures reliable insulin measurement.**Other Names**: Insulin FPP Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: Fasting/postprandial insulin standard; in India, used in diabetes clinics.**Purpose**: The test assesses 2 parameters including fasting insulin to guide insulin response evaluation, detect hyperinsulinemia, inform intervention.**Test Parameters**: 1. Fasting Insulin, 2. Postprandial Insulin.**Pretest Condition**: Fasting 10-12 hours required (postprandial 2 hours after meal/glucose load); patients should report metabolic risk.**Specimen**: 3 mL serum in 1 SST (multiple draws), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on weight, family diabetes, PCOS symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected insulin issues including diabetes, benefits of assessment, and minimal discomfort from multiple venipunctures.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or meal timing can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High fasting/postprandial insulin indicates resistance, necessitating specialist input.**Specialist Consultation**: Diabetologists or endocrinologists should be consulted for management.**Additional Supporting Tests**: HOMA-IR, OGTT for confirmation.**Test Limitations**: Postprandial timing critical; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Metabolic Studies India 2023. |
